Quantcast
Researchers Create Vaccine For Dust Mite Allergies

Researchers Create Vaccine For Dust Mite Allergies

Richard C. Lewis, University of Iowa Vaccine reduced lung inflammation to allergens in lab and animal tests If you’re allergic to dust mites (and chances are you are), help may be on the way. Researchers at the University of Iowa have...

Latest asthma Stories

2014-07-28 13:25:26

University of Manchester Scientists from The University of Manchester have discovered why medication to treat asthma and pneumonia can become ineffective. The findings, published in Nature Medicine, show that drugs widely used to treat lung diseases work with the body clock. In the UK pneumonia, which is caused by an infection, affects around 1 in 1000 adults each year and is more serious for babies, young children, the elderly, smokers and those with an underlying health condition....

2014-07-24 12:27:40

While Expressing Concerns about Reimbursement, EU5 Payers Look Favorably on Identifying Anti-IL5 Therapy-Responsive Patients, According to Findings from Decision Resources Group BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first once-daily long-acting beta2 agonist/inhaled corticosteroid...

2014-07-24 08:33:35

MONROVIA, Calif., July 24, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release second quarter financial results after market close on Thursday, July 31, 2014. Xencor management will host a webcast and conference call the same day at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial...

2014-07-15 08:28:23

MONROVIA, Calif., July 15, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Kurt Gustafson to its board of directors. Mr. Gustafson will also serve as chair of Xencor's audit committee and as a member of the compensation committee. Xencor also announced the promotion of John R....

2014-07-10 20:22:35

VIENNA, Va., July 10, 2014 /PRNewswire-USNewswire/ -- Allergy & Asthma Network, a leading nonprofit patient education organization, invites you to join its "2014 Venom Allergy 101" webinar on July 24, 2014, at 7 p.m. EST. This webinar is perfect for the summer as stinging insects abound in outdoor areas. Learn how to protect yourself from stings as well as how to respond and treat a potential allergic reaction. Venom allergies are caused by five types of insects: honey bees,...

2014-07-09 16:28:51

Results from Earlier Clinical Trials Published Today in the New England Journal of Medicine TARRYTOWN, N.Y. and PARIS, July 9, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. All doses of dupilumab met the primary endpoint...

2014-07-09 16:28:46

VIENNA, Va., July 9, 2014 /PRNewswire-USNewswire/ --- Allergy & Asthma Network, a leading nonprofit patient education organization, is pleased to announce that its Anaphylaxis Community Expert (ACE) volunteer program is partnering with the American Latex Allergy Association (ALAA) to increase awareness about life-threatening latex allergies. Latex allergies impact 8-12 percent of health care workers and 1-6 percent of the U.S. population, according to the U.S. Centers for Disease...

2014-07-01 11:31:24

American Thoracic Society In a new study of the causes underlying respiratory symptoms in military personnel returning from duty in Iraq and Afghanistan, a large percentage of veterans had non-specific symptoms that did not lead to a specific clinical diagnosis. Most patients who did receive a diagnosis had evidence of asthma or nonspecific airway hyperreactivity, which may have been due in some cases to aggravation of pre-existing disease by deployment exposures. "Earlier studies of...

2014-06-27 23:07:53

GlaxoSmithKline agreed to pay $105 million to settle claims by California, New York, and more than 40 other states that it illegally promoted three of its antidepressants and asthma drugs. Flood Law Group is investigating potential Paxil claims in light of this recent settlement. (PRWEB) June 27, 2014 GlaxoSmithKline agreed to pay $105 million to settle claims by California, New York, and more than 40 other states that it illegally promoted three of its antidepressants and asthma drugs,...

2014-06-24 23:06:47

According to a new report from BCC Research, the global market for pulmonary drug delivery systems is expected to grow to $43.9 billion by 2018 with a compound annual growth rate (CAGR) of 6.2% from 2013 to 2018. The dry powder inhalers category is the fastest moving segment in this market, growing at a significant five-year CAGR of 12.5%. (PRWEB) June 24, 2014 BCC Research (http://www.bccresearch.com) reveals in its new report, PULMONARY DRUG DELIVERY SYSTEMS: TECHNOLOGIES AND GLOBAL...


Latest asthma Reference Libraries

Journal of Allergy and Clinical Immunology
2012-05-14 11:51:18

The Journal of Allergy and Clinical Immunology is a medical journal established in 1929 as the Journal of Allergy. It is published by Elsevier. It obtained its current name in 1971. It is the official journal of the American Academy of Allergy, Asthma and Immunology. This journal publishes timely clinical papers, instructive case reports, and detailed examinations of state-of-the-art equipment and techniques to clinical allergists, immunologists, dermatologists, internists, and other...

More Articles (1 articles) »
Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related